Liver transplantation for sclerosing XXXX .

@entity1 @entity295 @entity190 @entity5 @entity991 @entity29 @entity134 @entity201 @entity1140 @entity204 @entity694 @entity255 @entity1141
The clinical course of 37 @entity1 who underwent 46 liver transplantations for primary (n = 33) and secondary (n = 4) sclerosing @entity255 was reviewed. The median follow-up was 37 months. The @entity1 and graft survivals for @entity1 with @entity991 at 1, 2, and 5 years were 96.9%, 91.6%, 87.9%, and 83.1%, 74.2%, 65.2%, respectively. In the @entity1 with @entity991 ( @entity991 ), prior surgery except for simple cholecystectomy was associated with significantly greater operative time and @entity190 . No @entity201 was identified at the time of transplantation. Human leukocyte antigen typing for @entity991 @entity1 was heavily weighed toward B8 (58.8%) compared with control (11.8%). Sixty-two percent of @entity1 with @entity991 also had @entity29 . Moderate or severe rejection requiring OKT3, "rescue therapy" with @entity1140 , or retransplantation was relatively higher in @entity1 with @entity29 (70%) versus @entity1 without @entity29 (36.4%) and a matched control group (37.5%). Progressive @entity29 was seen in 6 of 19 @entity1 , with 3 developing @entity5 and a @entity1141 . Two @entity1 in the entire group died of @entity295 and 3 of @entity694 (2 recurrent and 1 primary). These data demonstrate that excellent survival results can be achieved in this group of @entity1 . Rejection is frequent and often severe and @entity134 refractory. @entity694 represents the most frequent cause of @entity204 in @entity991 @entity1 after liver transplantation and demands constant attention.
